Aman's Global Market Intelligence

Executive dashboard

S&P 500 · Fri close7,711.76−0.25%

Nasdaq Composite · Fri26,402.42−0.52%

Dow · Fri53,559.99−0.02%

Russell 2000 · Fri2,972.37−1.39%

VIX · Fri close14.43−0.55%; complacent

U.S. 2Y / 10Y · Fri4.34% / 4.73%+14 / +6 bp

U.S. futures · overnightES −0.19%NQ +0.07% · YM −0.23% · RTY −0.09%

Dollar index99.603−0.10%

WTI / Gold$85.63 / $4,487.70+2.67% / +0.21%

Nikkei / Hang Seng66,174 / 25,454−0.35% / −0.51%

Shanghai Composite3,973.21+0.53%

Euro STOXX 50 / DAX6,485.67 / 26,569.99Friday closes; pre-open

FTSE 10010,824.26Friday close; pre-open

1 · Energy shock

Oil is the new overnight variable

WTI was $85.63, 2.67% above Friday's settlement. Reuters and Bloomberg both linked weaker Asian risk appetite and firmer oil to Iran tensions. The verified price move matters more than unsourced geopolitical detail: it can lift inflation compensation and pressure duration equities. WTI data · Reuters headline feed

2 · Rates & breadth

High yields still dominate speculative themes

Friday's official 2Y/10Y curve was 4.34%/4.73%, while Russell fell 1.39% and tracked quantum names lost 5%–8%. Overnight RTY futures were only 0.09% lower—not a confirmed recovery. Treasury curve · RTY futures

3 · Earnings

CRDO Tuesday, AVGO Wednesday

Nasdaq's live calendar adds Credo, Dell and Palo Alto Tuesday; Broadcom, Snowflake and HPE Wednesday; Ciena and several cloud names Thursday. AVGO remains the central custom-silicon/networking read-through. Consensus fields are vendor estimates, not company guidance. Sep. 1 · Sep. 2

Market drivers

Macro, central banks and geopolitics

Monday cross-asset signal: ES −0.19%, Dow futures −0.23%, oil +2.67%, gold +0.21% and DXY −0.10%. That is a cautious inflation/geopolitical mix, though NQ +0.07% prevents a broad capitulation label. ES · NQ
Asia: Nikkei −0.35% and Hang Seng −0.51%; Shanghai +0.53%. Reuters independently characterized Asian shares as weaker with oil and yields elevated. Dispersion argues against extrapolating a single regional risk signal.
Federal Reserve: Chair Warsh's Aug. 28 speech emphasized price stability and short-term rates as the predominant dual-mandate tool. Friday's front-end yield jump is the market confirmation. The next scheduled FOMC is Sep. 15–16 with projections. speech · calendar
Release timing: at 08:30 Italy, U.S. cash trading and most U.S. releases are still hours away. BEA lists July trade for Sep. 3 at 08:30 ET / 14:30 CEST. Avoid treating previews as released facts. BEA schedule

Earnings, regulation and rotation

AI expectations: NVIDIA reported $96.2B Q2 revenue (+106% y/y), $89.0B data-center revenue (+117%) and guided $108.0B ±2% for Q3, with no China data-center compute revenue assumed. Friday's −4.57% shows that great fundamentals do not prevent valuation/rates compression. NVIDIA IR · 10-Q
Latest SEC screen: EDGAR's live 8-K Atom feed was updated Aug. 31 02:31 ET. The newest tracked-theme item found was SeeQC's Aug. 28 8-K for termination of a material agreement—not a positive quantum operating milestone. SEC feed
Rotation test: Friday punished semis, AI power/cooling and quantum while Salesforce held its post-earnings gap. Monday confirmation requires breadth and volume after Europe/U.S. open; overnight index futures alone cannot validate single-stock leadership.
Regulation: no fresh, primary-source export-control, FDA or other tracked-theme regulatory action was verified by cutoff. Standing risks remain material but are not presented as new catalysts.

Theme dashboards

AI · fragile

Oil and yields raise the hurdle

Leaders/laggards: Friday CRM +1.57%; MRVL −10.28%, NVDA −4.57%, VRT −4.53%, CRDO −3.12%, ANET −2.84%.
Catalysts: CRDO Tuesday and AVGO Wednesday directly test optics/networking/custom silicon; CIEN Thursday tests carrier/data-center networking.
Risk: elevated expectations, 4.73% 10Y, export limits, customer concentration, capex digestion and power/cooling execution. Wait for repair rather than average into vertical breaks.

Quantum · extreme risk

No verified commercial de-risking

Friday: PSQL +96.81% debut, while IONQ −7.68%, QUBT −5.78%, RGTI −5.17% and QBTS −5.08%.
Primary update: SeeQC disclosed termination of a material agreement; PSQL's SEC filing verifies combination/listing mechanics only. Neither establishes better bookings, error rates or fault tolerance. SeeQC 8-K · PSQL 6-K
Risk: early revenue, cash burn, dilution, architecture uncertainty, warrants/float and squeezes. Borrow availability and fees are not sourced.

Peptide biotech · evidence wait

Safety/body-composition focus

Friday: LLY −0.13%, NVO −1.41%, small-cap/high-binary VKTX −5.02%.
Registry update: NCT07154719 is a recruiting randomized Phase 4 tirzepatide study (estimated n=50) measuring fat-free mass by DXA plus MRI and bone/muscle biomarkers; updated Aug. 27. It is exploratory/limited-size and not a commercial efficacy readout. registry
TRIUMPH-2: completed Phase 3, actual n=1,152, but no result statistics posted. No efficacy/safety claim is inferred. registry

Ranked ideas — quotas are ceilings; all triggers conditional

1Conditional bullish

CRM · Salesforce (NYSE)

Risk class: large-cap enterprise cloud; post-earnings gap / very high near-term volatility. Classification: relative-strength continuation only. Applicable horizon: day trade and 1–4 week swing; 3–12+ months only after recurring-growth/FCF review. Direction uncertain.

Thesis/catalyst: Friday close $256.00, +1.57%, preserving Thursday's gap despite Nasdaq weakness. This week's cloud reports can reinforce or reject software breadth.

Evidence / counterargument: exchange-session data confirm two-day relative strength. Counter: the gap is extended, rates and oil are hostile, and post-earnings support can fail abruptly.

Entry/confirmation: require a stable $252–256 base, then a break of Friday's high with strong volume and positive software breadth; no gap chase. Invalidation/downside: close below $248; $240 is the next reference, and gaps can skip stops. Key risks: rates, valuation, competition, execution, AI monetization quality and gap reversal. price source

Thesis Confidence 70

Risk 92

Opportunity 57

1Avoid / failed-rebound bearish

PSQL · Pasqal Holding (Nasdaq)

Risk class: newly listed de-SPAC quantum; extreme price-discovery/liquidity risk. Classification: avoid chasing; bearish only after confirmed failed rebound. Applicable horizon: day observation only; 1–4 weeks wait for structure; no 3–12+ month call without financial evidence. Direction highly uncertain. Short loss is unlimited.

Thesis/catalyst: Friday close $19.11, +96.81% against the $9.71 reference after combination completion. Listing mechanics are not commercial proof.

Evidence / counterargument: SEC verifies symbols and combination; exchange data verify price. Counter: float-driven momentum may extend dramatically, and future neutral-atom milestones could improve value.

Entry/confirmation: no blind short; bearish only below $17 followed by failed reclaim—simplest action is avoid. Invalidation/downside: bearish view invalid above $20.10 on sustained volume. Key risks: unknown effective float here, halts, warrants, squeeze, dilution and minimal chart history. Borrow/fees unknown. SEC · price

Thesis Confidence 78

Risk 100

Opportunity 35

2Avoid pending repair

IONQ · IonQ (NYSE)

Risk class: speculative quantum; high duration, valuation, cash-burn and event risk. Classification: avoid, not an immediate short. Applicable horizon: 1–4 week watch; 3–12+ months only with commercial/unit-economics proof. Direction uncertain. Short loss is unlimited.

Thesis/catalyst: Friday close $39.20, −7.68%, rejecting Thursday's rebound as Treasury yields rose. No weekend primary filing supplied a commercial offset.

Evidence / counterargument: price trend and SEC feed support caution. Counter: a verified contract, hardware milestone or speculative breadth rebound can reverse the stock sharply.

Entry/confirmation: no long until reclaim above $42.46 with positive quantum breadth; avoidance strengthens below $38. Invalidation/downside: avoidance expires above $44.86. Key risks: commercialization, dilution, cash burn, architecture competition, rates, volatility and squeeze. Borrow/fees unknown. SEC · price

Thesis Confidence 74

Risk 98

Opportunity 40

No second/third bullish idea and no third bearish idea: oil, yields, closed U.S. cash and Friday's damaged theme breadth leave no compelling evidence-backed additions. Waiting is a position.

Watchlist — five names

Ticker / exchange / risk class	Classification & horizon	Thesis, catalyst & counterargument	Confirmation, invalidation & risks	C / R / O
Watch AVGO Nasdaq · mega-cap custom silicon/networking; event-gap risk	Event watch; day/swing after Sep. 2 results; 3–12 months on guidance/FCF.	Friday $368.79, −0.74%. Week's key AI ecosystem test. Counter: high expectations; Nasdaq's $2.83 consensus is vendor data, not guidance.	Wait for report/base; above $372 constructive, below $360 weakens. Event gaps, leverage, customer concentration, rates.	80 / 96 / 62
Watch CRDO Nasdaq · mid/large-cap high-beta connectivity; earnings gap risk	Sep. 1 event watch; day/swing only after price discovery; long term on revenue/FCF.	Friday thematic laggard −3.12%; Tuesday earnings can test optical/connectivity demand. Counter: strong AI demand may overpower rate pressure.	No pre-event entry; require post-report base and sector breadth. Failure to reclaim Friday range is weak. Valuation, concentration, supply, gaps.	74 / 97 / 58
Watch NVDA Nasdaq · mega-cap; post-earnings/high-expectations risk	Gap repair; day/swing after base; long term on growth, margins and FCF.	$217.55, −4.57% despite exceptional reported growth and $108B ±2% guide. Counter: fundamentals remain very strong.	Reclaim $220 then $225; below $214 weakens. China/export, valuation, margin, rates and capex concentration.	91 / 91 / 56
Watch VRT NYSE · large-cap/high-beta AI power & cooling	Broken setup; swing only after repair; long term on backlog, margins and FCF.	$257.08, −4.53%; structural data-center power demand remains plausible but Friday invalidated momentum.	Reclaim $263 then $269; below $255 worsens. Capex timing, execution, valuation, rates and input costs.	77 / 89 / 49
Watch LLY NYSE · mega-cap pharma; clinical/regulatory binary risk	Relative-strength watch; 1–4 weeks; 3–12 months on franchise/data. Not a pre-readout trade.	$1,174.61, −0.13%. TRIUMPH-2 completed Phase 3, n=1,152; no results posted. Counter: valuation and unknown efficacy/safety statistics.	Require healthcare-relative strength and reclaim $1,180; below $1,150 weakens. Safety, discontinuation, reimbursement, competition, manufacturing.	83 / 75 / 55

C / R / O = Thesis Confidence / Risk / Opportunity. Confidence scores evidence quality, never guaranteed outcome probability.

Changes versus the 2026-08-30 report

Regime downgraded: from neutral/risk-off under the surface to risk-off/selective because tradable overnight data now show WTI +2.67%, ES −0.19% and two of three major Asian benchmarks lower.
Rates warning persists: no new official cash curve exists after Friday; 2Y/10Y remain frozen at 4.34%/4.73%. Overnight futures have not demonstrated a broad duration reversal.
Ideas retained but scores trimmed: CRM remains the only conditional long, with Opportunity 60→57 and Risk 91→92 due to oil/rates. PSQL and IONQ remain avoids; no levels are optimized after the fact.
Watchlist change: CRDO replaces ANET because its Sep. 1 earnings are now the nearest direct AI-connectivity binary. This is a watch, not a pre-event recommendation.
Primary-source additions: SEC's live feed identifies a SeeQC agreement termination; ClinicalTrials.gov adds an Aug. 27 Phase 4 tirzepatide body-composition update. Neither supports a bullish re-rating.

Important catalysts: next 7–30 days

Aug. 31 · Europe/U.S. cash opens
First volume test of oil/yield pressure. Require sector breadth; 08:30 Italy precedes European cash open and U.S. pre-market liquidity is thin.

Sep. 1 · earnings — Medtronic pre-market; PANW, DELL, CRDO, MDB after close
AI connectivity, servers, cybersecurity and database demand. Nasdaq timing/consensus can change. Nasdaq

Sep. 2 · after U.S. close — Broadcom, Snowflake and HPE
Custom silicon/networking, cloud consumption and enterprise infrastructure. AVGO's $2.83 vendor consensus is not guidance. Nasdaq

Sep. 3 · 14:30 CEST — July U.S. trade balance
Official BEA timing; potential dollar/rates/cyclical catalyst. BEA

Sep. 3 · earnings — CIEN pre-market; ZS, IOT, DOCU, PATH after close
Networking, cybersecurity, IoT and software read-through. Nasdaq

Sep. 10 / Oct. 1 — NVIDIA dividend record / payment
Company release states a $0.25 quarterly dividend; date-certain but not a major valuation catalyst. NVIDIA

Sep. 15–16 — FOMC + Summary of Economic Projections
Largest 30-day duration event for all three themes. Federal Reserve

Peptide pipeline — readout date not asserted
TRIUMPH-2 is complete but registry has no posted statistics or public result date. Do not anticipate efficacy, safety or regulatory outcomes. ClinicalTrials.gov

Bottom line by horizon

Day trade

Bias: risk-off until oil cools and cash breadth improves. CRM only after a stable base; do not chase or blind-short PSQL.

Biggest risk: geopolitical/oil headlines and gap-through stops. Invalidation: caution eases if WTI reverses below Friday's range, 2Y/10Y fall and semis/small caps reclaim Friday ranges.

1–4 week swing

Bias: high cash/selectivity through CRDO/AVGO and toward FOMC. Broken NVDA/VRT structures need repair; quantum needs operating evidence.

Biggest risk: sticky energy inflation plus earnings expectation saturation. Invalidation: broad Russell/semiconductor participation with lower yields upgrades the regime.

3–12+ month investment

Bias: favor profitable AI infrastructure only after valuation/FCF work; demand commercial proof in quantum and full statistics/regulatory evidence in peptide biotech.

Biggest risk: persistent inflation, capex digestion, dilution or failed endpoints. Invalidation: durable disinflation plus verified order and FCF acceleration supports more duration exposure.

Data quality & methodology

Session/timestamp: generated 08:30:17 CEST; market cutoff about 08:19 CEST. Yahoo query2 metadata placed futures observations around 06:19 UTC. Asia is Aug. 31; Europe and U.S. cash values are Aug. 28 closes. Treasury is the official Aug. 28 curve.
Live research completed: direct Yahoo query2 retrieval for 33 symbols; direct Treasury XML; SEC live 8-K Atom feed; four Google News RSS screens; ClinicalTrials.gov v2; three Nasdaq earnings calendars; direct Fed and BEA pages; plus CNBC and Stooq diagnostics. This exceeds five meaningful retrieval calls across market data, news and primary company/regulatory information.
Cross-checks: Monday Yahoo pulls reproduce Friday closes quoted in Sunday's frozen report. Reuters and Bloomberg independently reported weaker Asian risk appetite with oil higher; Yahoo independently quantifies WTI +2.67%. SEC establishes filing date/type; ClinicalTrials.gov supplies phase, enrollment, endpoints and update date.
Limitations and retries: Yahoo query1 returned HTTP 429, but query2 succeeded. Stooq URLs returned HTTP 404 and CNBC's multi-symbol request returned code 1; these failures are not used to declare market data unavailable because Yahoo succeeded. Generic web search/extraction returned payment-required errors; direct APIs/pages succeeded. BLS returned HTTP 403, so no BLS release date is asserted. European cash was not unavailable—it was not yet open at the scheduled cutoff.
News discipline: Google RSS headlines are discovery sources. Material geopolitical interpretation is limited to points independently carried by Reuters/Bloomberg and corroborated by price; no operational detail or forecast is invented.
Technical method: percentage moves use latest versus prior futures settlement/close. Triggers are conditional references, not predicted fills. Gaps can bypass invalidation levels.
Biotech method: registry evidence is explicit about Phase 4, randomized design, estimated n=50, DXA primary measure, safety/body-composition context and lack of commercial readout. TRIUMPH-2 has no posted results statistics; cash runway or regulatory timing is not inferred.
Scores: Confidence = evidence quality, not outcome probability. Risk rises with duration, valuation, event gaps, liquidity, cash burn, leverage, dilution and binary exposure. Opportunity balances timing, evidence and asymmetry.

Sources

Research disclaimer: Research and paper-tracking only—not individualized, guaranteed, fiduciary, legal or medical advice. The initial two weeks are paper-tracking. Prices can gap beyond invalidation levels; shorts can lose more than invested. Verify live quotes, liquidity, taxes and suitability independently.